Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary diseaseopen access
- Authors
- Yoon, Ho Il; Lee, Chang-Hoon; Kim, Deog Kyeom; Park, Geun Min; Lee, Sang-Min; Yim, Jae-Joon; Kim, Jae-Yeol; Lee, Jae Ho; Lee, Choon-Taek; Chung, Hee Soon; Kim, Young Whan; Han, Sung Koo; Yoo, Chul-Gyu
- Issue Date
- 2013
- Publisher
- DOVE MEDICAL PRESS LTD
- Keywords
- chronic obstructive pulmonary disease; acute exacerbation; levofloxacin; cefuroxime
- Citation
- INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, v.8, pp 329 - 334
- Pages
- 6
- Journal Title
- INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- Volume
- 8
- Start Page
- 329
- End Page
- 334
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/15080
- DOI
- 10.2147/COPD.S41749
- ISSN
- 1176-9106
1178-2005
- Abstract
- Background: Antibiotic treatment is one of the major pharmacologic treatments for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the choice of antibiotic depends on the local resistance pattern. A multicenter, randomized, controlled trial was done in patients with AECOPD to compare the efficacy of levofloxacin with that of cefuroxime axetil. Methods: Patients with AECOPD and without radiographic evidence of pneumonia were enrolled and randomized to either levofloxacin 500 mg daily or cefuroxime 250 mg twice daily in the mild-moderate exacerbation group, or 500 mg twice daily in the severe exacerbation group, for seven days. Clinical efficacy and microbiologic response were evaluated 5-7 days after the last dose. Results: Treatment was clinically successful in 90.4% of patients in the levofloxacin group, and in 90.6% of patients in the cefuroxime group (95% confidence interval -9.40 to 10.91), within a noninferiority margin of 10%. The microbiologic response appeared to be higher in the levofloxacin group, but the difference was not statistically significant. The safety profile was similar in both groups. Conclusion: Levofloxacin is not inferior to cefuroxime with regard to clinical efficacy in treating AECOPD.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/15080)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.